Literature DB >> 23009227

The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin.

E A Marcus1, N Inatomi, G T Nagami, G Sachs, D R Scott.   

Abstract

BACKGROUND: Penicillins inhibit cell wall synthesis; therefore, Helicobacter pylori must be dividing for this class of antibiotics to be effective in eradication therapy. Identifying growth responses to varying medium pH may allow design of more effective treatment regimens. AIM: To determine the effects of acidity on bacterial growth and the bactericidal efficacy of ampicillin.
METHODS: H. pylori were incubated in dialysis chambers suspended in 1.5-L of media at various pHs with 5 mM urea, with or without ampicillin, for 4, 8 or 16 h, thus mimicking unbuffered gastric juice. Changes in gene expression, viability and survival were determined.
RESULTS: At pH 3.0, but not at pH 4.5 or 7.4, there was decreased expression of ~400 genes, including many cell envelope biosynthesis, cell division and penicillin-binding protein genes. Ampicillin was bactericidal at pH 4.5 and 7.4, but not at pH 3.0.
CONCLUSIONS: Ampicillin is bactericidal at pH 4.5 and 7.4, but not at pH 3.0, due to decreased expression of cell envelope and division genes with loss of cell division at pH 3.0. Therefore, at pH 3.0, the likely pH at the gastric surface, the bacteria are nondividing and persist with ampicillin treatment. A more effective inhibitor of acid secretion that maintains gastric pH near neutrality for 24 h/day should enhance the efficacy of amoxicillin, improving triple therapy and likely even allowing dual amoxicillin-based therapy for H. pylori eradication.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23009227      PMCID: PMC3474890          DOI: 10.1111/apt.12059

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  41 in total

Review 1.  Helicobacter pylori: its role in disease.

Authors:  M J Blaser
Journal:  Clin Infect Dis       Date:  1992-09       Impact factor: 9.079

2.  The complete genome sequence of the gastric pathogen Helicobacter pylori.

Authors:  J F Tomb; O White; A R Kerlavage; R A Clayton; G G Sutton; R D Fleischmann; K A Ketchum; H P Klenk; S Gill; B A Dougherty; K Nelson; J Quackenbush; L Zhou; E F Kirkness; S Peterson; B Loftus; D Richardson; R Dodson; H G Khalak; A Glodek; K McKenney; L M Fitzegerald; N Lee; M D Adams; E K Hickey; D E Berg; J D Gocayne; T R Utterback; J D Peterson; J M Kelley; M D Cotton; J M Weidman; C Fujii; C Bowman; L Watthey; E Wallin; W S Hayes; M Borodovsky; P D Karp; H O Smith; C M Fraser; J C Venter
Journal:  Nature       Date:  1997-08-07       Impact factor: 49.962

3.  The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection.

Authors:  P O Erah; A F Goddard; D A Barrett; P N Shaw; R C Spiller
Journal:  J Antimicrob Chemother       Date:  1997-01       Impact factor: 5.790

4.  The effects of nocturnal acid breakthrough on Helicobacter pylori eradication.

Authors:  Jin Il Kim; Soo-Heon Park; Jae Kwang Kim; In Sik Chung; Kyu Won Chung; Hee Sik Sun
Journal:  Helicobacter       Date:  2002-12       Impact factor: 5.753

5.  Gastric adenocarcinoma and Helicobacter pylori infection.

Authors:  J Parsonnet
Journal:  West J Med       Date:  1994-07

6.  Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface.

Authors:  David R Scott; Elizabeth A Marcus; Yi Wen; Jane Oh; George Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-16       Impact factor: 11.205

7.  The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects.

Authors:  R H Hunt; D Armstrong; M Yaghoobi; C James
Journal:  Aliment Pharmacol Ther       Date:  2009-12-15       Impact factor: 8.171

8.  Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy.

Authors:  Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Chise Kodaira; Masafumi Nishino; Mutsuhiro Ikuma; Takashi Ishizaki; Akira Hishida
Journal:  Helicobacter       Date:  2007-08       Impact factor: 5.753

9.  Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant.

Authors:  J E Sjöström; H Larsson
Journal:  J Med Microbiol       Date:  1996-06       Impact factor: 2.472

Review 10.  The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview.

Authors:  R Jain; L H Danziger
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

View more
  28 in total

1.  One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.

Authors:  Takuma Kagami; Mitsushige Sugimoto; Hitomi Ichikawa; Shu Sahara; Takahiro Uotani; Mihoko Yamade; Yasushi Hamaya; Moriya Iwaizumi; Satoshi Osawa; Ken Sugimoto; Hiroaki Miyajima; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2015-10-02       Impact factor: 2.953

2.  Phosphorylation-dependent and Phosphorylation-independent Regulation of Helicobacter pylori Acid Acclimation by the ArsRS Two-component System.

Authors:  Elizabeth A Marcus; George Sachs; Yi Wen; David R Scott
Journal:  Helicobacter       Date:  2015-05-22       Impact factor: 5.753

3.  Gastric acid-dependent diseases: a twentieth-century revolution.

Authors:  George Sachs; Jai Moo Shin; Keith Munson; David R Scott
Journal:  Dig Dis Sci       Date:  2014-07       Impact factor: 3.199

4.  The effect of different combinations of antibiotic cocktails on mice and selection of animal models for further microbiota research.

Authors:  Jing Xu; Hao-Ming Xu; Yao Peng; Chong Zhao; Hai-Lan Zhao; Wenqi Huang; Hong-Li Huang; Jie He; Yan-Lei Du; Yong-Jian Zhou; You-Lian Zhou; Yu-Qiang Nie
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-29       Impact factor: 4.813

Review 5.  Eradication of Helicobacter pylori Infection.

Authors:  Elizabeth A Marcus; George Sachs; David R Scott
Journal:  Curr Gastroenterol Rep       Date:  2016-07

Review 6.  Helicobacter pylori: future perspectives in therapy reflecting three decades of experience.

Authors:  Tajana Filipec Kanizaj; Nino Kunac
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

7.  Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.

Authors:  Hiroshi Matsumoto; Akiko Shiotani; Ryo Katsumata; Minoru Fujita; Rui Nakato; Takahisa Murao; Manabu Ishii; Tomoari Kamada; Ken Haruma; David Y Graham
Journal:  Dig Dis Sci       Date:  2016-09-22       Impact factor: 3.199

8.  Helicobacter pylori impedes acid-induced tightening of gastric epithelial junctions.

Authors:  Elizabeth A Marcus; Olga Vagin; Elmira Tokhtaeva; George Sachs; David R Scott
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-08-29       Impact factor: 4.052

9.  Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics.

Authors:  E A Marcus; G Sachs; D R Scott
Journal:  Aliment Pharmacol Ther       Date:  2015-08-04       Impact factor: 8.171

Review 10.  Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.

Authors:  Mitsushige Sugimoto; Takahisa Furuta
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.